Cyclin‑dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials

• E. Panagiotou ^[1] ; G. Gomatou ^[1] ; I. P. Trontzas ^[1] ; N. Syrigos ^[1] ; E. Kotteas ^[1]
  1. [1] Oncology Unit, Sotiria General Hospital, Athens School of Medicine, 152 Mesogeion Avenue, 11527 Athens, Greece
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 2, 2022, págs. 161-192
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Cyclin-dependent kinases (CDKs) play a key regulating role in the cell cycle, which is almost universally altered in cancer, leading to sustained proliferation. Early pan-CDK inhibitors showed poor results in clinical trials for solid malignancies, as the lack of selectivity produced significant toxicity. The production of more selective inhibitors led to significant develop- ments in cancer therapy, as CDK4/6 inhibitors in combination with endocrine therapy changed the landscape of the treat- ment of hormone-receptor positive (HR +) metastatic breast cancer. Recently, Trilaciclib demonstrated benefits regarding hematological toxicity compared to placebo when administered in combination with chemotherapy in small cell lung cancer.

    Newer agents, such as SY-5609, a selective CDK7 inhibitor, have also shown promising results in early clinical trials. In this paper, we review the data from clinical trials of CDK inhibitors in solid tumors, either as a monotherapy or in combination with other agents, with an emphasis on novel agents and potential new indications for this drug class.